Business Description
Medicenna Therapeutics Corp
NAICS : 325410
SIC : 3741
ISIN : CA58490H1073
Total Employee Number:
17Description
Medicenna Therapeutics Corp is the development and commercialization of IL-2, IL-4 and IL-13Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its platforms are Superkine, BISCUIT, TEMASK, Publications, and Scientific Publications.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 52.53 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -2.2 | |||||
3-Year EPS without NRI Growth Rate | -2.5 | |||||
3-Year FCF Growth Rate | -3.1 | |||||
3-Year Book Growth Rate | -58.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.39 | |||||
9-Day RSI | 29.22 | |||||
14-Day RSI | 31.79 | |||||
3-1 Month Momentum % | -32.17 | |||||
6-1 Month Momentum % | -53.86 | |||||
12-1 Month Momentum % | -50.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.52 | |||||
Quick Ratio | 1.52 | |||||
Cash Ratio | 1.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.2 | |||||
Shareholder Yield % | 0.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -174.75 | |||||
ROA % | -101.47 | |||||
ROIC % | -9670.84 | |||||
3-Year ROIIC % | -4336.17 | |||||
ROC (Joel Greenblatt) % | -18254.89 | |||||
ROCE % | -167.4 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 15.05 | |||||
Price-to-Tangible-Book | 15.05 | |||||
EV-to-EBIT | -1.46 | |||||
EV-to-EBITDA | -1.47 | |||||
EV-to-Forward-Revenue | 70.75 | |||||
EV-to-FCF | -1.83 | |||||
| Price-to-Net-Current-Asset-Value | 15.05 | |||||
Earnings Yield (Greenblatt) % | -68.49 | |||||
FCF Yield % | -46.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:MDNAF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medicenna Therapeutics Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.159 | ||
| Beta | 2.7973 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.68 | ||
| Volatility % | 85.81 | ||
| 14-Day RSI | 31.79 | ||
| 14-Day ATR ($) | 0.027202 | ||
| 20-Day SMA ($) | 0.302322 | ||
| 12-1 Month Momentum % | -50.48 | ||
| 52-Week Range ($) | 0.25 - 1.43 | ||
| Shares Outstanding (Mil) | 92.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medicenna Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medicenna Therapeutics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-11-12 | In 134 days | ||
| General meeting for 2026 | 2026-09-25 10:00 | In 87 days | ||
| First quarter earnings results for 2027 | 2026-07-31 | In 30 days | ||
| Fourth quarter earnings results for 2026 | 2026-06-26 | 0.29 (+1.47%) | ||
| Annual report for 2026 | 2026-06-25 | 0.28 (-2.00%) | ||
| Guidance call for 2026 | 2026-04-21 15:00 | 0.45 (+3.13%) | ||
| BIO-Europe Spring Conference | 2026-03-23 | 0.50 (-4.63%) | ||
| 38(th) Annual ROTH Conference | 2026-03-22 | 0.50 (-4.63%) | ||
| BIO Investment and Growth Summit | 2026-03-02 | 0.67 (-3.25%) | ||
| 7(th) Annual Glioblastoma Summit: Trailblazing Next-Generation Glioblastoma & Glioma Therapies | 2026-02-19 10:00 | 0.63 (+0.48%) |
Show
Entries
Medicenna Therapeutics Corp Frequently Asked Questions
What is Medicenna Therapeutics Corp(MDNAF)'s stock price today?
The current price of MDNAF is $0.30. The 52 week high of MDNAF is $1.43 and 52 week low is $0.25.
When is next earnings date of Medicenna Therapeutics Corp(MDNAF)?
The next earnings date of Medicenna Therapeutics Corp(MDNAF) is 2026-07-31 Est..
Does Medicenna Therapeutics Corp(MDNAF) pay dividends? If so, how much?
Medicenna Therapeutics Corp(MDNAF) does not pay dividend.
Guru Commentaries on OTCPK:MDNAF
No articles.
Press Release
Articles on Medicenna Therapeutics Corp
No articles.
Headlines
See More- 1
Jun 26, 2026
Medicenna Therapeutics Corp. GAAP EPS of -C$0.22
Seeking Alpha • 7:51am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers